The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes

Kim, Yaeni; Lim, Ji Hee; Kim, Min Young; Kim, Eun Nim; Yoon, Hye Eun; Shin, Seok Joon; Choi, Bum Soon; Kim, Yong‐Soo; Chang, Yoon Sik; Park, Cheol Whee

doi:10.1681/asn.2017060627

Cited by 164 publications

(140 citation statements)

References 40 publications

Supporting

Mentioning

134

Contrasting

Order By: Relevance

“…Currently, as the most frequent complication of DM , DN has been found in 40% or more of the novel DM cases . Nevertheless, information regarding DN‐associated pathogens remains elusive.…”

Section: Discussionmentioning

confidence: 99%

RETRACTED: XBP1 inhibits mesangial cell apoptosis in response to oxidative stress via the PTEN/AKT pathway in diabetic nephropathy

Wang

Qiu

et al. 2019

FEBS Open Bio

View full text Add to dashboard Cite

Diabetic nephropathy ( DN ) is a complication of diabetes mellitus ( DM ) that frequently results in renal disease, and is characterized by a variety of symptoms, including albuminuria. It has been shown that apoptosis of glomerular mesangial cells ( MC s) can aggravate albuminuria and contribute to the development of diabetic glomerulosclerosis. Hence, determination of the mechanisms leading to MC apoptosis may help us gain insights into the pathogenesis of DN . As our understanding of the role of high glucose ( HG ) in MC apoptosis remains elusive, we explored the interplay between X‐box binding protein 1 ( XBP 1) and MC apoptosis in this study. XBP 1 was observed to be downregulated both in vivo and in vitro . Treatment of XBP 1‐overexpressing cells with HG resulted in a decrease of reactive oxygen species ( ROS ) and a suppression of cell apoptosis, concomitant with decreases in cleaved caspase‐3 and Bax. Subsequent analyses demonstrated that XBP 1 overexpression inhibited the expression of phosphatase and tensin homolog deleted on chromosome ten ( PTEN ) and enhanced the activation of AKT in MC s exposed to HG . In addition, XBP 1‐induced injuries in MC were reversed by overexpression of PTEN , and XBP 1 inhibited apoptosis, which was mediated by the activated PTEN / AKT signaling pathway. Thus, our data indicate that XBP 1 can activate the PTEN / AKT signaling pathway, thereby alleviating oxidative stress caused by HG or MC apoptosis. These findings suggest that XBP 1 may have potential in the development of treatment methods for DN .

show abstract

Section: Discussionmentioning

confidence: 99%

RETRACTED: XBP1 inhibits mesangial cell apoptosis in response to oxidative stress via the PTEN/AKT pathway in diabetic nephropathy

Wang

Qiu

et al. 2019

FEBS Open Bio

View full text Add to dashboard Cite

show abstract

“…ADIPOR2, encoding adiponectin receptor2, has been implicated in cardiovascular diseases [40,41], fatty liver disease [42], diabetes [43], diabetic nephropathy [44], and bone metabolic disorders [45]. In each of these pathogenic conditions forced overexpression of ADIPOR2 ameliorates the disease process.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of miR-19a protects neurons against ischemic stroke through modulating glucose metabolism and neuronal apoptosis

Wang

Liu

et al. 2019

Cell Mol Biol Lett

View full text Add to dashboard Cite

Background: Accumulating evidence has shown that altered microRNA (miR) modulation is implicated in the pathologies of ischemic stroke. However, it is unclear whether and how hsa-miR-19a-3p mediates cerebral ischemic injury. Herein, we investigated the functional role of miR-19a-3p in cerebral ischemic injury and explored its underlying regulatory mechanism. Methods: In vivo ischemic/reperfusion (I/R) neuronal injury and in vitro oxygenglucose deprivation (OGD) were established. Expression of miR-19a-3p was determined by quantitative real-time polymerase chain reaction (qRT-PCR). Glucose uptake, lactate production, and apoptosis were determined. ADIPOR2 was predicted as a target of miR-19a-3p in silico and experimentally validated by qRT-PCR, Western blot analysis and luciferase assay assays. Results: MiR-19a expression was significantly downregulated and upregulated in rat neurons and astrocytes, respectively (P < 0.01). A significantly elevated level of miR-19a-3p was found in I/R and OGD models in comparison to sham/control groups (P < 0.01). Expression of the glycolysis enzyme markers LDHA, PKM2, HK2, Glut1 and PDK1, apoptosis-related factors levels, apoptosis, glucose uptake, and lactate production were significantly repressed by both I/R and OGD (P < 0.01 in each case). Moreover, miR-19a-3p mimic aggravated, while miR-19a-3p inhibitor alleviated, the above observations. Adipor2 was predicted and confirmed to be a direct target of miR-19a. Furthermore, restoration of Adipor2 reversed miR-19a-3p-induced effects. Conclusions: Collectively, our results indicate that elevated miR-19a-3p mediates cerebral ischemic injury by targeting ADIPOR2. MiR-19a-3p attenuation thus might offer hope of a novel therapeutic target for ischemic stroke injury treatment.

show abstract

“…AdipoRON effectively improved insulin sensitivity and restored glucose homeostasis via the activation of AdipoR1-AMPK-PGC1α and AdipoR2-PPARα signaling pathways (162). AdipoRON treatment also mimicked adiponectin's established anti-diabetic effects (163) and ability to enhance cellular capacity for mitigating oxidative-stress (162,164), enhancing lipid/glucose oxidation in mitochondria (162,164), anti-inflammatory responses (162,(164)(165)(166)(167), lifeprolonging effect (162,163), anti-cancer effects (168,169), procell survival and anti-apoptotic effect (170,171), neuronal- (172,173), reno- (174,175), and cardio-/vascular-protective effects (165,(176)(177)(178)(179). However, exciting AdipoRON research in animal models has not been translated to establishment of a drug for human use and the search continues for additional small molecule AdipoR agonists which have little or no toxicity.…”

Section: Adiporonmentioning

confidence: 97%

Examining the Potential of Developing and Implementing Use of Adiponectin-Targeted Therapeutics for Metabolic and Cardiovascular Diseases

Liu¹,

Sweeney

2019

Front. Endocrinol.

View full text Add to dashboard Cite

Cardiometabolic diseases encompass those affecting the heart and vasculature as well as other metabolic problems, such as insulin resistance, diabetes, and non-alcoholic fatty liver disease. These diseases tend to have common risk factors, one of which is impaired adiponectin action. This may be due to reduced bioavailability of the hormone or resistance to its effects on target tissues. A strong negative correlation between adiponectin levels and cardiometabolic diseases has been well-documented and research shown that adiponectin has cardioprotective, insulin sensitizing and direct beneficial metabolic effects. Thus, therapeutic approaches to enhance adiponectin action are widely considered to be desirable. The complexity of adiponectin structure and function has so far made progress in this area less than ideal. In this article we will review the effects and mechanism of action of adiponectin on cardiometabolic tissues, identify scenarios where enhancing adiponectin action would be of clinical value and finally discuss approaches via which this can be achieved.

show abstract

The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes

Cited by 164 publications

References 40 publications

RETRACTED: XBP1 inhibits mesangial cell apoptosis in response to oxidative stress via the PTEN/AKT pathway in diabetic nephropathy

RETRACTED: XBP1 inhibits mesangial cell apoptosis in response to oxidative stress via the PTEN/AKT pathway in diabetic nephropathy

Inhibition of miR-19a protects neurons against ischemic stroke through modulating glucose metabolism and neuronal apoptosis

Examining the Potential of Developing and Implementing Use of Adiponectin-Targeted Therapeutics for Metabolic and Cardiovascular Diseases

Contact Info

Product

Resources

About